OBJECTIVE: P2X(7) receptor (P2X(7)R), upon its stimulation with extracellular ATP, modulates several inflammatory responses in different cell types. No information is available on its presence in human adipocytes and its potential involvement in the chronic inflammation associated with metabolic syndrome (MS). Therefore, we evaluated P2X(7)R presence and functional activity in adipocytes from visceral (VAT) and subcutaneous (SAT) adipose tissue of patients with MS and controls (CTL). METHODS: Adipocyte gene expression of TNFα, IL-6 and PAI-1 (by realtime-PCR) and their plasma concentrations (ELISA); P2X(7)R expression (realtime-PCR, Western blot and immunofluorescence); P2X(7)R functional activity (intracellular calcium fluxes by fluorimetry); cytokine release from adipocytes (ELISA). The inflammasome components were also determined. RESULTS: In VAT, TNFα, IL-6 and PAI-1 were more expressed in MS than in CTL. These differences were confirmed in SAT for IL-6 and PAI-1. Plasma IL-6, PAI-1 and TNFα levels were higher in MS. P2X(7)R mRNA and protein, identified in both VAT and SAT, were more abundant in MS than in CTL. Immunofluoresce confirmed the typical "ring-like" arrangement of P2X(7)R at the plasma membrane. Benzoyl-benzoyl-ATP raised intracellular calcium both in VAT and SAT, and induced IL-6, TNFα and PAI-1 release in both MS and CTL cells. This effect was partially inhibited by KN62, specific human P2X(7)R blocker, or by P2X(7)R gene silencing. The inflammasome was more activated in MS than in CTL adipocytes. CONCLUSION: Human adipocytes express functionally active P2X(7)R, which modulate the release of inflammatory cytokines, at least in part via inflammasome activation. Adipocytes from MS patients show an enhanced P2X(7)R expression, which might contribute to the subclinical inflammatory status characterizing these patients and conferring them an increased CV risk.
OBJECTIVE:P2X(7) receptor (P2X(7)R), upon its stimulation with extracellular ATP, modulates several inflammatory responses in different cell types. No information is available on its presence in human adipocytes and its potential involvement in the chronic inflammation associated with metabolic syndrome (MS). Therefore, we evaluated P2X(7)R presence and functional activity in adipocytes from visceral (VAT) and subcutaneous (SAT) adipose tissue of patients with MS and controls (CTL). METHODS: Adipocyte gene expression of TNFα, IL-6 and PAI-1 (by realtime-PCR) and their plasma concentrations (ELISA); P2X(7)R expression (realtime-PCR, Western blot and immunofluorescence); P2X(7)R functional activity (intracellular calcium fluxes by fluorimetry); cytokine release from adipocytes (ELISA). The inflammasome components were also determined. RESULTS: In VAT, TNFα, IL-6 and PAI-1 were more expressed in MS than in CTL. These differences were confirmed in SAT for IL-6 and PAI-1. Plasma IL-6, PAI-1 and TNFα levels were higher in MS. P2X(7)R mRNA and protein, identified in both VAT and SAT, were more abundant in MS than in CTL. Immunofluoresce confirmed the typical "ring-like" arrangement of P2X(7)R at the plasma membrane. Benzoyl-benzoyl-ATP raised intracellular calcium both in VAT and SAT, and induced IL-6, TNFα and PAI-1 release in both MS and CTL cells. This effect was partially inhibited by KN62, specific humanP2X(7)R blocker, or by P2X(7)R gene silencing. The inflammasome was more activated in MS than in CTL adipocytes. CONCLUSION:Human adipocytes express functionally active P2X(7)R, which modulate the release of inflammatory cytokines, at least in part via inflammasome activation. Adipocytes from MS patients show an enhanced P2X(7)R expression, which might contribute to the subclinical inflammatory status characterizing these patients and conferring them an increased CV risk.
Authors: Kim L Beaucage; Andrew Xiao; Steven I Pollmann; Matthew W Grol; Ryan J Beach; David W Holdsworth; Stephen M Sims; Mark R Darling; S Jeffrey Dixon Journal: Purinergic Signal Date: 2013-11-13 Impact factor: 3.765